TACSTD2 and triple-negative breast carcinoma: Sacituzumab govitecan (SG) is the first ADC directed against Trop-2 and was recently approved in China for patients with metastatic triple-negative breast cancer (mTNBC) who have undergone two or more lines of chemotherapy.